ENYO Pharma new headquarters opening

On the 18th of November, 2019 ENYO Pharma and Edelris inaugurated their new main offices in the Laënnec Bioparc located in Lyon. It was a great moment and we had the honor to host Mr. David Kimelfeld (Metropolis President) and Mr. Michel Le Faou (Municipal Councilor representing the mayor of the 8th arrondissement) for our “biotechnologies and territory development” round table. This new headquarter localization will open promising horizons for collaborations and contribute to ENYO’s growth.

Read more »


8-12 November, 2019
Boston, Massachusetts

ENYO Pharma attended the AASLD meeting in Boston and presented four posters as well as performed an oral presentation around FXR agonists in HBV and NASH.

During the conference, ENYO Pharma sponsored a Symposium to discuss recent advances in the understanding of the replication of Hepatitis B (HBV) and the potential ability of Farnesoid X receptor (FXR) agonists, such as EYP001, to provide a functional cure for HBV.

Read more »

Targeting Immunometabolism in Autoimmune Diseases and Inflammation conference

22 October, 2019
New-York, USA

ENYO Pharma will participate to the “Targeting Immunometabolism in Autoimmune diseases and Inflamamtion conference” in New York and will present a poste entitled “A novel small molecule modulating mitochondrial activity improves inflammation in a diet-induced NASH model”

Read more »

International HBV Meeting

1-5 October, 2019
Melbourne, Australia

The ENYO Pharma team will be present in Melbourne in October to present, in collaboration with Pr. André’s Inserm team, a poster entitled “Interplay and Recruitment of FXR and HBx on cccDNA and Role on Viral Transcription” describing FXR mechanism of action in HBV inhibition.

Read more »


27th of Sept – 1st of Oct
Barcelona, Spain

ENYO Pharma will attend the ESMO conference in order to raise awareness of it novel, potent chemistry which induces Immunogenic Cell Death in multiple tumour types and inhibits tumor growth in animal models.

Read more »